Cargando…

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY

Detalles Bibliográficos
Autores principales:	Wei, Yujun, Qian, Kun, Wang, Lili, LI, Fei, Wang, Nan, Peng, Bo, Wen, Yanan, Wang, Lu, Xu, Lingmin, Jin, Xiangshu, Dou, Liping, Liu, Dai-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428308/ http://dx.doi.org/10.1097/01.HS9.0000967900.54514.e6

Ejemplares similares

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
por: León-Rodríguez, Eucario, et al.
Publicado: (2022)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
por: Farhan, Shatha, et al.
Publicado: (2017)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

M247. PAST AND ANTICIPATED HUMILIATION MAY CONTRIBUTE TO ANXIETY AND PRONENESS TO PSYCHOSIS EXPERIENCES IN A COMMUNITY SAMPLE
por: Lee, Stuart, et al.
Publicado: (2020)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
por: Hilberink, Jacobien, et al.
Publicado: (2023)

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
por: Gao, Lei, et al.
Publicado: (2020)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia
por: Zhao, Haitao, et al.
Publicado: (2020)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
por: Ren, Xiying, et al.
Publicado: (2023)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
por: Borst, Carla, et al.
Publicado: (2023)

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies
por: Zhao, Yingxin, et al.
Publicado: (2022)

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
por: Wang, Ling, et al.
Publicado: (2018)

S274: A NEW, EFFECTIVE, SAFE, NON-MYELOABLATIVE CONDITIONING REGIMEN WITH A HLA-MATCHED SIBLING DONOR FOR THE SEVERE SICKLE CELL PHENOTYPE IN ADULTS
por: Ihlem, Rahal, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT)
por: Ramzi, Mani, et al.
Publicado: (2020)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
por: Jonas, Brian A., et al.
Publicado: (2023)

Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia
por: Jing, Yu, et al.
Publicado: (2016)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

Unraveling the High Activity of Ylide-Functionalized Phosphines in Palladium-Catalyzed Amination Reactions: A Comparative Study with (Cy)JohnPhos and PtBu(3)
por: Scharf, Lennart T., et al.
Publicado: (2019)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
por: Hilberink, Jacobien R., et al.
Publicado: (2023)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e2qh9258021nsb65o8r311d0lb